Global InformationVAMP regimen information
| VAMP regimen | |
|---|---|
| Specialty | oncology |
VAMP regimen or VAMP chemotherapy is a four-drug combination chemotherapy regimen, used today in the treatment of Hodgkin lymphoma.[1][2] It was one of the earliest combination chemotherapy regimens, originally developed as a treatment for childhood leukemia by a group of researchers at the National Cancer Institute led by Emil Frei and Emil Freireich.[3][4] The first clinical trial of VAMP began in 1961.[3] Because it was the first time that four chemotherapeutic agents were used at once, the trial was highly controversial at its time.[3] Although new combination chemotherapy regimens have replaced the use of VAMP in the treatment of childhood leukemia, VAMP is considered an important precursor to modern treatments, confirming the effectiveness of combination chemotherapy and leading to the use of combination chemotherapy regimens to treat other types of cancer.[2][5][6]
The VAMP regimen developed by Freireich and Frei was a combination of vincristine, amethopterin, mercaptopurine, and prednisone.[3][5] Now, other combinations and doses that are referred to as VAMP, including C-VAMP and a VAMP regimen that replaces the mercaptopurine of the original combination with doxorubicin.[7][1][8][9] All these regimens take advantage of the synergistic effects of combining multiple chemotherapy agents.[1]
- ^ a b c "VAMP". 2011-12-22.
- ^ a b DeVita, Vincent T.; Chu, Edward (2008-11-01). "A History of Cancer Chemotherapy". Cancer Research. 68 (21): 8643–8653. doi:10.1158/0008-5472.CAN-07-6611. ISSN 0008-5472. PMID 18974103.
- ^ a b c d Mukherjee, Siddhartha (2011). The Emperor of All Maladies. NY: Scribner. pp. 132–134, 139–48.
- ^ Chabner, Bruce A.; Roberts, Thomas G. (January 2005). "Chemotherapy and the war on cancer". Nature Reviews Cancer. 5 (1): 65–72. doi:10.1038/nrc1529. ISSN 1474-1768. PMID 15630416. S2CID 205467419.
- ^ a b Pritchard, Justin R.; Lauffenburger, Douglas A.; Hemann, Michael T. (October 2012). "Understanding resistance to combination chemotherapy". Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 15 (5–6): 249–257. doi:10.1016/j.drup.2012.10.003. ISSN 1532-2084. PMC 3975170. PMID 23164555.
- ^ Ribatti, Domenico (May 2012). "Sidney Farber and the treatment of childhood acute lymphoblastic leukemia with a chemotherapeutic agent". Pediatric Hematology and Oncology. 29 (4): 299–302. doi:10.3109/08880018.2012.678969. ISSN 1521-0669. PMID 22568792. S2CID 31176962.
- ^ VAMP/C-VAMP infusional chemotherapy as induction treatment for previously untreated multiple myeloma doi=10.1016/0959-8049(95)96048-I
- ^ http://jco.ascopubs.org/content/25/3/332.full Final Results of a Prospective Clinical Trial With VAMP and Low-Dose Involved-Field Radiation for Children With Low-Risk Hodgkin's Disease. 2007
- ^ Donaldson, S. S.; Hudson, M. M.; Lamborn, K. R.; Link, M. P.; Kun, L; Billett, A. L.; Marcus, K. C.; Hurwitz, C. A.; Young, J. A.; Tarbell, N. J.; Weinstein, H. J. (July 2002). "VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial". J. Clin. Oncol. 20 (14): 3081–7. doi:10.1200/jco.2002.12.101. PMID 12118021.